

Index

- abnormal bereavement, 8, 9
  - characteristics, 102
  - classification issues, 347
  - and cortisol levels, 36
  - diagnostic criteria, 23
  - diagnostic issues, 36
  - and melancholia, 36–37, 46, 97
- Abrams, R., 19, 27
- Accreditation Council of Graduate Medical Education (ACGME) (USA), 352
- ACTH *see* adrenocorticotrophic hormone (ACTH)
- AD *see* Alzheimer’s disease (AD)
- Addison’s disease
  - differential diagnosis, 111
  - etiology, 111
- adjustment disorder with depressed mood, 47, 97
  - adolescents, 102
  - differential diagnosis, 101–102
  - and suicide risk, 102
- adolescents
  - adjustment disorder with depressed mood, 102
  - cognitive-behavior therapy, 245
  - electroconvulsive therapy, 165–70
    - case studies, 168–70
    - efficacy, 165–67, 244
    - safety issues, 165
  - manic-depressive illness, 245
  - melancholia, 103–104
    - comorbidity, 91–93, 103
    - pharmacotherapy, 244–50
    - prevalence, 103
    - recommendations, 250
    - sample heterogeneity, 245–46
    - psychotherapy, 244–45
- adrenalectomy, 62
- adrenal glands
  - atrophy, 62
  - and stress, 62–63
- adrenocorticotrophic hormone (ACTH), 64
  - and pregnancy, 33
  - release, 64
  - and stress responses, 309
- adrenocorticotropin *see* adrenocorticotrophic hormone (ACTH)
- AEPs *see* auditory evoked potentials (AEPs)
- affective disorders, convulsive therapy, 155
- affective reactions, 8
- African-Americans, suicide rates, 126
- agitation
  - with melancholia, suicide risk assessment, 135–36
  - symptoms, 16
- agomelatine, 290
- Akiskal, H. S., 21
- alcohol abuse
  - and depressive mood disorders, 255, 301
  - and melancholia, 108–109
    - pharmacotherapy, 255–56
  - and sleep, 357
  - and suicide risk, 137
- alcoholism, genetic factors, 255
- Alzheimer’s disease (AD)
  - differential diagnosis, 106
  - with melancholia, pharmacotherapy, 260–61
  - and pseudodementia, 261
    - differential diagnosis, 118, 158
- American Academy of Child and Adolescent Psychiatry, 165
- American College of Obstetricians and Gynecologists, 291
- American Journal of Psychiatry*, 200, 288
- American Psychiatric Association (APA), 6, 8
  - classification issues, 365
  - dexamethasone suppression test assessment, 70
  - suicidal patient guidelines, 143
  - Task Force on ECT, 167
    - recommendations, 182
  - see also* *Diagnostic and Statistical Manual of Mental Disorders* (DSM)
- amines, secondary vs tertiary, 199, 211
- Amish, suicide risk, 136
- amitriptyline, 50
  - effectiveness, 202–203
    - adolescents, 247
  - effects on suicide rates, 140
    - studies, 141
  - and electroconvulsive therapy compared, 157
  - with haloperidol, 224
  - melancholia treatment, 211
  - studies, 54

523 Index

- amobarbital, electroencephalography studies, 323
- amygdala
  - metabolism, 318–19
  - and stress responses, 308–11
- Angst, J., 21
- animal studies
  - abnormal neuroplasticity, 314–15
  - noradrenergic dysfunction, 314
  - reward mechanisms, 315
  - serotonin function, 312–13
  - stress responses, 306, 308
- anterior cingulate cortex, volume reduction, 317–18, 319
- anterior insular cortex, increased metabolism, 319–20
- anticonvulsants
  - approved, 50
  - diabetes with melancholia treatment, 264–65
  - effects on seizure, 188
  - efficacy, 24
  - epilepsy with melancholia treatment, 260
  - in mania treatment, 23
  - manic-depressive illness treatment, 228–29
  - neonatal issues, 242
- antidepressants, 5–6
  - Alzheimer's disease with melancholia treatment, 261
  - with antipsychotics, 223–24
  - approved, increase, 50
  - comparisons
    - biased, 197, 198, 199–01
    - methodology issues, 200
    - placebo effects, 200–201
    - unfavorable, 198
  - controlled studies
    - bias, 198
    - limitations, 197
    - reviews, 199
    - volunteer criteria, 198
  - diabetes with melancholia treatment, 264–65
  - dosing issues, 214, 247–48
  - drug–drug interactions, 265
  - drug-switching, 213–14, 217–18
  - effects on glucocorticoid receptors, 311
  - effects on suicide rates, 140–42
    - meta-analyses, 140–41
    - studies, 142
  - efficacy, tricyclics vs SSRIs, 201–204
  - fetal safety issues, 243
  - and glucose metabolism, 226
  - mania induction, 22–23
    - incidence, 22
  - and manic-depressive illness
    - mood switch risk, 225–26
    - treatment, 226–27
  - marketing strategies, 51
  - medical illness with melancholia treatment, 261–62
  - meta-analyses, 197, 199–00, 201–204
  - novel, and industry influences, 197–99
  - overdose, lethality, 142–43
  - postpartum depression treatment, 163
  - prescriptions, 50, 141–42
  - selection criteria, 240
  - side-effects, 205
  - simultaneous application, 217
  - and suicide prevention, 132
  - teratogenicity, 240–41
  - thyroid disease with melancholia treatment, 265
  - use of term, 7–8
  - vs electroconvulsive therapy, 156, 157, 158, 161, 188–90
  - in pregnancy, 164
  - suicide risk, 159
  - see also* monoamine oxidase inhibitors (MAOIs); selective serotonin reuptake inhibitors (SSRIs); tricyclic antidepressants (TCAs)
- antipsychotics
  - with antidepressants, 223–24
  - approved, 50
  - drug augmentation, 217
  - drug–drug interactions, 265
  - fetal safety issues, 243
  - indications, 223–24
  - side-effects, 223, 224
  - use of term, 7–8
- anxiety disorders
  - differential diagnosis, 109
  - with melancholia, suicide risk assessment, 135–36
- anxious depression, 54–55
- APA *see* American Psychiatric Association (APA)
- apathetic syndromes
  - differential diagnosis, 109–13
  - and neurologic diseases, 113–18
- apathy
  - associated conditions, 264
  - symptoms, 112
- apolipoprotein E<sub>4</sub> gene, and Alzheimer's disease, 106
- approach–withdrawal theories, of hemisphere specialization, 322
- Arateus, on melancholia, 3
- Archives of General Psychiatry*, 200
- aripiprazole, 224
- Ashby, D., 141–42
- Asperger syndrome, with melancholia, 104
- atypical depression, 9, 54, 97
  - age of onset, 98
  - comorbidity, 98
  - differential diagnosis, 98–99
  - prevalence, 98
  - symptoms, 98, 278
  - treatment, 99
  - see also* seasonal affective disorder (SAD)
- auditory evoked potentials (AEPs), 323–24
  - advantages, 324
  - limitations, 324
  - mood disorder studies, 324
- Australia
  - antidepressant studies, 202
  - electroconvulsive therapy studies, 166
  - suicide rates, 126, 140–41

524 Index

- autism
  - with melancholia, 104
  - treatment, 104
- avolitional syndromes, differential diagnosis, 112–13
- Baillarger, Jules-Gabriel-François, 4, 18
- Baltimore Epidemiologic Catchment Area (USA), 252
- basal ganglia disease, differential diagnosis, 291
- Baxter, Richard, on melancholia, 3
- BDI *see* Beck Depression Inventory (BDI)
- BDNF *see* brain-derived neurotrophic factor (BDNF)
- BDRS (Brief Depression Rating Scale), 94
- Bech–Rafaelson Melancholia Scale (BRMS), 94
- Beck Depression Inventory (BDI), 50, 93
  - applications, 94
- behavior disorders, classification, 1
- Benazzi, F., 21, 55
- Bennett, A. E., 153
- benzodiazepines
  - and breast-feeding, 244
  - in catatonia diagnosis, 31, 161
  - effectiveness, elderly, 253
  - effects on seizure, 188
  - and fetal safety, 239
- bereavement
  - use of term, 46–47
  - see also* abnormal bereavement
- Berger, Hans, 321, 323
- beta-blockers, effects on seizure, 188
- Bethlem Hospital, 4
- bilateral electroconvulsive therapy (BL-ECT), 184
  - energy dosing, 186
  - and right unilateral electroconvulsive therapy compared, 184
- biological clock, 356
- bipolar depression, 8, 46
  - antidepressant-induced, 22–23
  - early studies, 19
  - electroconvulsive therapy, 172–74
  - case studies, 173–74
- bipolar disorders
  - Bipolar I, 8–9, 19
    - studies, 21
  - Bipolar II, 8–9, 19
    - longitudinal studies, 20–21
    - studies, 21
  - case studies, 22
  - diagnostic criteria, 8–9, 18
  - psychopathologic studies, 20
- bipolarity, lack of support for, 24
- bipolar–unipolar dichotomy
  - clinical studies, 20–22
  - criticisms, 19, 20
  - early studies, 19
  - research issues, 21
  - vs continuum model, 19–20
- bipolar–unipolar overlap, 23
  - issues, 24
  - studies, 21
  - twin studies, 23
- BL-ECT *see* bilateral electroconvulsive therapy (BL-ECT)
- borderline personality disorder, 99
- BPRS (Brief Psychotic Rating Scale), 166
- bradykinesia, 88
- bradykinetic syndromes, differential diagnosis, 112–13
- bradyphrenia, 88
- brain
  - feedback mechanisms, 63
  - see also* hemispheres
- brain-derived neurotrophic factor (BDNF), 315–16
  - abnormalities, 316
  - and reward mechanisms, 315
- brain injury
  - and depressive mood disorders, 317
  - see also* traumatic brain injury (TBI)
- brain metabolism, abnormal, in melancholia, 318–20, 332, 343
- brain structure
  - abnormal
    - in melancholia, 317–18, 329, 346
    - postmortem studies, 317–18
- breast cancer, drug-induced, 224
- breast-feeding
  - melancholia in, pharmacotherapy, 239–44
  - and psychotropic drugs, 243–44
- brief depression, 46
  - differential diagnosis, 101
- Brief Depression Rating Scale (BDRS),
  - applications, 94
- Brief Psychotic Rating Scale (BPRS), 166
- brief recurrent depression, 9
- Bright, Timothy, on melancholia, 3
- Britain *see* United Kingdom (UK)
- British Journal of Psychiatry*, 288
- BRMS (Bech–Rafaelson Melancholia Scale), 94
- brofaromine, 290
- bromocriptine
  - drug augmentation, 216
  - Parkinson’s disease with melancholia treatment, 259
- Brooklyn State Hospital (USA), 154
- bupropion, 225
  - effectiveness, elderly, 253
  - heart disease with melancholia treatment, 262–63
  - mania induction, 23
  - in smoking cessation therapy, 256
  - trials data, 350
- Burke, W. J., 203
- Burton, Robert, on melancholia, 3
- California (USA)
  - electroconvulsive therapy, adolescents, 165
  - Medicaid, 270
- cAMP *see* cyclic adenosine monophosphate (cAMP)

525 Index

- Canada, electroconvulsive therapy studies, 166
- cancers
  - breast cancer, 224
  - and depression risk, 111
- Cannon, Walter, 62–63
- Capgras syndrome, and psychotic depression, 30
- carbamazepine
  - drug–drug interactions, 265
  - in mania treatment, 23
  - manic-depressive illness treatment, 229
  - neonatal issues, 242
- Cardiazol *see* pentylenetetrazol
- cardiovascular disease
  - and electroconvulsive therapy, 170
  - with melancholia, pharmacotherapy, 262–64
  - see also* heart disease
- Carroll, Bernard J., 64–65, 66, 68, 75
- on dexamethasone suppression test, 66, 69, 70–71
- Carroll Rating Scale (CRS), 94
  - applications, 94
- catalepsy, 30
- catatonia, 9, 46, 88
  - antidepressant treatment, 161
  - case studies, 30–31, 32
  - diagnosis, 31
  - diagnostic criteria, 25
  - differential diagnosis, 30, 161
  - electroconvulsive therapy, 161–63
    - case studies, 162–63
    - efficacy, 161
  - malignant, 161
  - and melancholia, 30, 32, 97
  - pharmacotherapy, 224–25
  - retarded, 162
  - symptoms, 31, 161
- CBT *see* cognitive-behavior therapy (CBT)
- CCKs (cholecystokinins), 317
- central nervous system (CNS), and
  - hypothalamic–pituitary–adrenal axis, 64
- cerebral hemispheric instability, and
  - manic-depressive illness, 329–30
- cerebrovascular disease, elderly, 105
- cerebrovascular stroke, differential diagnosis, 114
- CFS (chronic fatigue syndrome), 112
- characterological conditions, and
  - electroconvulsive therapy, 171–72
- characterological depression, 46
- Charney, D. S., 57
- chemical messengers, 63
- chemical neurotransmission, 62
- child abuse
  - identifying, 357
  - stress responses, 306
- Child and Adolescent Consortium (USA),
  - electroconvulsive therapy studies, 165–66
- childhood stress, and melancholia, 306
- children
  - cognitive-behavior therapy, 245
  - of depressed mothers, 305–306
  - electroconvulsive therapy, 165–70
    - case studies, 168–70
    - efficacy, 167, 244
  - manic-depressive illness, 245
  - marital conflict effects on, 306
  - melancholia, 103–104
    - comorbidity, 91–93, 103
    - pharmacotherapy, 244–50
    - prevalence, 103
    - prevention, 354–58
    - recommendations, 250
    - sample heterogeneity, 245–46
  - psychotherapy, 244–45
  - temperament, 302
- Children’s Depression Rating Scale-Revised, 248
- China, suicide rates, 125
- chlordiazepoxide, effectiveness, children and
  - adolescents, 249
- chlorpromazine
  - drug–drug interactions, 265
  - mood disorder treatment studies, 7–8
  - in postpartum depression treatment, 36
- cholecystokinins (CCKs), roles, 317
- chromosome 12, 362
- chronic depression, differential diagnosis, 101
- chronic fatigue syndrome (CFS), and melancholia,
  - differential diagnosis, 112
- chronicity, prevention, 358
- chronic renal disease, and depression risk, 111
- cimetidine, drug–drug interactions, 265
- circadian cycles
  - and CLOCK genes, 361–62
  - fetus, 356
  - and melancholia, 310
- citalopram
  - and breast-feeding, 243–44
  - effectiveness, 203
  - children and adolescents, 248
  - effects on suicide rates, 141
  - heart disease with melancholia treatment, 263, 264
  - Parkinson’s disease with melancholia treatment, 259
  - post-stroke depression treatment, 258
- clinical examination, 85–95
  - cognition, 90–91
  - mood, 87, 441
  - personality disorders, 91
  - psychomotor functioning, 88
  - for psychotic features, 89–90, 441
  - strategies, 86–87, 446
  - for suicidal thoughts, 90
  - for vegetative signs, 88–89
- CLOCK genes, 361
  - ethnic and racial differences, 361
  - localization, 361
  - mutations, 361
- clomipramine
  - effectiveness, 203
  - adolescents, 248
  - epilepsy with melancholia treatment, 260
- clonidine, in smoking cessation therapy, 256
- clozapine, 223–24
  - drug–drug interactions, 265
- CME (continuing medical education), 352
- CNS (central nervous system), 64

526 Index

- cocaine, and depressive mood disorders, 256
- cocaine withdrawal
  - comorbidity, 109
  - and melancholia, differential diagnosis, 109–10
  - pharmacotherapy, 256
- Cochrane Collaboration, 199, 203
- cognition, clinical examination, 90–91
- cognitive-behavior therapy (CBT)
  - in depression treatment, 218
  - effectiveness
    - adolescents, 245
    - children, 245, 248
  - in postpartum depression treatment, 243
- cognitive deficits
  - in melancholia, 327–28
  - studies, 327–28
- Colorado (USA), electroconvulsive therapy, adolescents, 165
- comas, 30
  - see also* insulin coma
- complications
  - melancholic patients
  - recommendations, 266–68
- consent issues, electroconvulsive therapy, 162, 167
- continuing medical education (CME), programs, 352
- continuous positive airway pressure (CPAP), 269
- convulsive therapy, 6–7
  - affective disorder treatment, 155
  - early studies, 153–55, 161
  - fear of treatment, 183
  - manic-depressive illness treatment, early studies, 153–54
  - mechanisms, future studies, 353–54
  - melancholia, 346
  - mood disorder treatment, 154
  - see also* electroconvulsive therapy (ECT); pentylentetrazol
- Cook, L. C., 153
- CORE study, 158, 160, 171, 189
- corpus callosum
  - reduced volume, 306, 317–18
  - and reduced metabolism, 319
- corticotropin *see* adrenocorticotrophic hormone (ACTH)
- corticotropin-releasing factor (CRF), 64
- corticotropin-releasing factor-1 receptor antagonists, 363
- corticotropin-releasing hormone (CRH)
  - and pregnancy, 33
  - release, 64
  - and stress responses, 309–11
- corticotropin-releasing hormone antagonists, 363
- cortisol
  - assays, 66
  - inhibition, 64
  - levels
    - and abnormal bereavement, 15–36
    - and depression, 65, 66
    - and premenstrual dysphoric disorder, 102
    - and stress, 302
    - and pregnancy, 33
    - resistance, 311
    - suppression, 354
    - urinary free, 67
- Cotard syndrome
  - case studies, 29
  - diagnostic criteria, 29
  - electroconvulsive therapy, 30
  - and psychotic depression, 29–30
- CPAP (continuous positive airway pressure), 269
- CREB (cyclic AMP response element-binding protein), 362
- CRF *see* corticotropin-releasing factor (CRF)
- CRH *see* corticotropin-releasing hormone (CRH)
- Crohn's disease, and depression, 111
- CRS *see* Carroll Rating Scale (CRS)
- crying, pathological, 116
- Culture and Depression*, 51
- Cushing's syndrome, 62
  - differential diagnosis, 111
  - etiology, 111
  - and hypercortisolemia, 64
- cyclic adenosine monophosphate (cAMP), 360
  - abnormalities, 311
- cyclic AMP response element-binding protein (CREB), 362
- cyclothymia, use of term, 18
- cyclothymic disorder, 8–9
- CYP2D6 gene, 359
- cytokines
  - abnormalities, and depression, 63
  - in depressed patients, 364
  - roles, 363–64
- D<sub>2</sub>-receptor genes, 362
- D<sub>3</sub>-receptor genes, 362
- Danish University Antidepressant Group, 203
- dawn simulation, 285
- DeCarolis, V., 157
- de Clérambault syndrome, and psychotic depression, 30
- delirium
  - case studies, 128–29
  - electroencephalography, 321
- delivery, and postpartum blues, 33
- delusional depression
  - diagnostic criteria, 25–26
  - see also* psychotic depression
- delusions
  - mood-congruent, 26–27
  - nihilistic, 29
  - see also* mood-incongruent delusions
- delusions of negation, case studies, 29
- dementia
  - differential diagnosis, 117–18
  - electroencephalography, 321
  - with melancholia, pharmacotherapy, 260–61
  - see also* Alzheimer's disease (AD); pseudodementia

527 Index

- dementia praecox, 4
  - and catatonia, 161
  - and manic-depressive illness compared, 18–19
  - see also* schizophrenia
- demyelinating disease, differential diagnosis, 116
- depressed mothers, 305–306
  - studies, 354–58
- depressed patients
  - compliance issues, 358
  - cytokines in, 364
  - electroencephalography studies, 321–23
  - sleep disturbances, 73, 325
  - suicide rates, 125
  - see also* melancholic patients
- depression
  - anxious, 54–55
  - chronic, 101
  - classification, 46–51
    - future trends, 346–49
    - issues, 46–48
  - cognitive-behavior therapy, 218
  - concept of, expansion, 50
  - and cortisol levels, 65, 66
  - and Crohn's disease, 111
  - delusional, 25–26
  - diagnostic criteria, 7, 46–51
    - choices, 47
    - in clinical practice, 47
  - cross-sectional vs longitudinal approaches, 55–56
  - industry influences, 50–51
  - limitations, 48–50
  - diagnostic issues, 62
  - epidemic, 50–51
  - genetic risk factors, 543
  - geriatric, 9
  - interpersonal therapy, 218
  - involutional, 9
  - irritable, 54
  - and Lyme disease, 111
  - and mania, 4, 18
  - markers, 63, 66, 77, 325
    - neurobiologic, 328
  - mild, 51, 54
  - non-nuclear, 57
  - nuclear, 57
  - and pancreatic carcinoma, 111
  - post-schizophrenia, 106
  - prevalence, 49–50
  - psychotherapies, 2
  - rating scales, 91–95
  - reactive, 3, 8
  - relapse, 73
    - risk factors, 358
  - seizure-related, 117
  - sleep electroencephalography studies, 73–74, 75, 76
  - subsyndromal, 46
  - superimposed, 106
  - and syphilis, 111
  - and thyroid-stimulating hormone levels, 72
  - and thyrotropin-releasing hormone levels, 72
  - treatment, issues, 47
  - twin studies, 49
  - use of term, 15
    - as buzzword, 51
    - Meyer's views, 6
  - and vascular disease, 106
  - vital, 8
  - see also* atypical depression; bipolar depression; brief depression; depressive mood disorders; double depression; endogenomorphic depression; endogenous depression; major depression; manic depression; melancholia; minor depression; neurotic depression; non-melancholic depression; postpartum depression; post-psychotic depression; post-stroke depression; prepartum depression; psychotic depression; puerperal depression; treatment-resistant depression (TRD); unipolar depression; vascular depression
- depression with catatonia or stupor, as severe melancholia, 30
- Depression Interview and Structured Hamilton, 92
- depression-like syndromes, and neurologic diseases, 113–18
- depressive mood disorders, 9
  - and alcohol abuse, 255, 301
  - and brain injury, 317
  - classification issues, 25–26, 346–49
  - diagnosis, 24, 85
  - differential diagnosis, 5
  - elderly, 105
  - family studies, 299–01
  - genetic factors, 255
  - genetic studies, 348
  - and lupus erythematosus, 111
  - melancholia as, 45, 58
  - mild, 46
  - misdiagnosis
    - case studies, 130
    - and suicide risk, 129–30
  - and multiple sclerosis, 116
  - and nicotine, 256
  - non-melancholic, 97
  - differential diagnosis, 98–03
  - norepinephrine function, Table 14.3, 304
  - pathophysiology, 298
  - prevention, and sleep, 356–57
  - as reactions, 6
  - and reward mechanisms, 315
  - risk factors, 111
  - serotonin function, Table 14.2, 313
  - and stress, 129–30
    - misdiagnosis, 129
  - and stroke, 317
  - and substance abuse, 256
  - and suicide risk, 125
  - threshold model, 56
  - treatment

528 Index

- depressive mood disorders (*cont.*)
  - algorithms, 47–48
  - issues, 8, 47
  - twin studies, 301, 303
  - under-diagnosis, 126–29
    - clinical ambiguities, 127
    - studies, 127
  - unrecognized
    - case studies, 127, 128–29
    - suicide risk, 126–29
  - see also* melancholia
- depressive reactions, 46
  - diagnostic criteria, 8
- depressive spectrum disease, 19
- depressive stupor
  - electroconvulsive therapy, 161–63
  - pharmacotherapy, 224–25
- desipramine
  - comparative studies, 199–00
  - effectiveness, 202–203
  - alcoholics, 255
  - melancholia treatment, 211
  - studies, 202
- dexamethasone, 64
  - in cortisol suppression, 65
- dexamethasone/corticotropin-releasing-hormone (DEX/CRH) test, 63
  - applications, 71
  - sensitivity, 71–72
- dexamethasone suppression test (DST), 26
  - assessment studies, 69–71
  - children and adolescents, 245
  - development, 64–65
  - diagnostic issues, 66–67, 108
    - as diagnostic screening test, 68–69
    - and electroconvulsive therapy, 68
      - outcomes evaluation, 181
  - limitations, 62, 63, 69, 109
  - non-suppression, incidence, 69
  - and Parkinson's disease, 115
  - and pregnancy, 33
  - principles, 65–66
  - prognostic value, 68
  - re-examination, 63
  - rejection, 71
  - schizophrenia diagnosis, 107–108
  - with sleep electroencephalography, 75
  - studies, 67–69
    - meta-analyses, 67
  - and suicide risk, 68, 138–39
  - technical issues, 66
  - validation, 66
- DEX/CRH test *see* dexamethasone/corticotropin-releasing-hormone (DEX/CRH) test
- dextroamphetamine, drug augmentation, 216
- diabetes, with melancholia, pharmacotherapy, 264–65
- Diagnostic and Statistical Manual of Mental Disorders* (DSM)
  - classification issues, future trends, 346–49, 365
  - cross-sectional approach, criticisms, 55–56
  - depression, 46–51
    - choices, 47, 536
    - classification issues, 46–48
    - diagnostic criteria limitations, 48–50
    - future trends, 346–49
    - limitations, 348
    - validity issues, 49
  - melancholia, future trends, 348–49
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-I) (1952), 6
  - depressive reactions, 8
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-II) (1968), 6, 8
  - criticisms, 8
  - depression, 7
  - reliability issues, 8
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-III) (1980), 8
  - bipolar disorder, 18
  - major depression, 18
  - melancholia, 55
  - mood-congruence, 26–27
  - mood disorders, 8
  - psychotic disorders, 25
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-III-R) (1987), 8
  - mood disorders, 9
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV) (1994)
  - abnormal bereavement, 23
  - depressive disorders, criticisms, 103
  - limitations, 2, 9
  - mood disorders, 9
  - psychotic disorders, 25, 106
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-V), proposals, 9
- differential diagnosis, melancholia, 58, 97–18
- diphenhydramine, drug–drug interactions, 265
- Donovan, S., 141
- dopamine dysfunction
  - and melancholia, 315
  - postmortem studies, 315
- dopaminergic agents, 290
- dorsolateral prefrontal cortex, reduced metabolism, 319
- dosing issues
  - antidepressants, 214, 247–48
  - elderly, 250
- double depression, 9, 100
  - differential diagnosis, 101
  - treatment resistance, 101
- dramatic-emotional personality disorders, comorbidity, 109
- Drevets, W. C., 312
- drug abuse, and melancholia, pharmacotherapy, 255, 256
- drug augmentation
  - limitations, 216
  - limitation trials, 214–15
  - options, 216–17
  - see also* lithium augmentation
- drug–drug interactions, 265
  - elderly, 250
  - in melancholia treatment, 265, 650



529 Index

- drug metabolism
  - and pharmacogenetics, 359–60
  - studies, 359
- drug overdose, antidepressants, 142–43
- drug overuse, and melancholia, differential diagnosis, 110
- drug-related depressive-like states, differential diagnosis, 109–10
- drugs
  - in electroconvulsive therapy, 188
  - mood disorder induction, 110, 655
- drug-switching
  - antidepressants, 213–14, 217–18
  - in melancholia treatment, 221
  - trials, 214–15
- DSM *see* *Diagnostic and Statistical Manual of Mental Disorders* (DSM)
- DSM-I *see* *Diagnostic and Statistical Manual of Mental Disorders* (DSM-I) (1952)
- DSM-II *see* *Diagnostic and Statistical Manual of Mental Disorders* (DSM-II) (1968)
- DSM-III *see* *Diagnostic and Statistical Manual of Mental Disorders* (DSM-III) (1980)
- DSM-III-R *see* *Diagnostic and Statistical Manual of Mental Disorders* (DSM-III-R) (1987)
- DSM-IV *see* *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV) (1994)
- DSM-V *see* *Diagnostic and Statistical Manual of Mental Disorders* (DSM-V)
- DST *see* dexamethasone suppression test (DST)
- dysrhythmias, electroencephalography, 321
- dysthymia, 8, 46, 97
  - classification issues, 347
  - diagnostic criteria, 100–101
  - differential diagnosis, 100–101
  - treatment, 101–10
- ECT *see* electroconvulsive therapy (ECT)
- ECT Review Group (UK), 156
- Edinburgh Postnatal Depression Scale, 94
- EEG *see* electroencephalography (EEG)
- ego, 6
- Einheitspsychose*, 4, 35
- elderly
  - antidepressants, meta-analyses, 200
  - cerebrovascular disease, 105
  - depressive mood disorders, 105
  - dosing issues, 250
  - drug–drug interactions, 250
  - electroconvulsive therapy, 170–71
    - case studies, 170–71
  - manic-depressive illness, lithium treatment, 227–28
  - melancholia, 104–106
    - case studies, 170–71
    - comorbidity, 105
    - continuation treatment, 254
    - maintenance treatment, 254
    - mortality rates, 250
    - pharmacotherapy, 250–54
    - prevalence, 104–105
    - recommendations, 254
    - risk factors, 105
  - pharmacotherapy
    - issues, 250–51
    - responsiveness, 251
  - suicide prevention errors, 126
  - and vascular brain disease, 251
  - vascular disease, 106
- electroconvulsive therapy (ECT)
  - adolescents, 165–70
    - case studies, 168–70
  - efficacy, 165–67, 244
  - safety issues, 165
  - advantages, 182, 224
  - applicability, 156–57
  - availability, recommendations, 352
  - barriers to, 174
  - benefits, 187
  - bipolar depression treatment, 172–74
    - case studies, 173–74
  - and cardiovascular disease, 170
  - catatonia treatment, 161–63
    - case studies, 162–63
  - efficacy, 161
  - and characterological conditions, 171–72
  - children, 165–70
    - case studies, 168–70
  - efficacy, 167, 244
  - concurrent medications, 188
  - consent issues, 162, 167
  - continuation
    - strategies, 188–90
    - studies, 189
  - contraindications, 184
  - Cotard syndrome treatment, 30
  - course design, 187–88
  - current, AC vs square wave, 184
  - depressive stupor treatment, 161–63
  - and dexamethasone suppression test, 68
  - early studies, 155
  - effective
    - achieving, 181–90
    - issues, 190
  - effective seizures, characterization, 185
  - efficacy, 24, 202
    - optimal, 354
  - elderly, 170–71
    - case studies, 170–71
  - electrode placement, 184
    - bilateral, 184
    - right unilateral, 184
  - electrode selection, 186
  - energy dosing, 186
  - epilepsy with melancholia treatment, 260
  - failure to administer, and suicide risk, 134
  - ineffective, studies, 187–88
  - mechanisms, 353–54
    - neuroendocrine hypothesis, 353
    - neurohumoral theory, 353–54
    - neurophysiologic hypotheses, 353
  - melancholia treatment, 174, 221
    - case studies, 157
  - effectiveness, 155–57, 211
  - issues, 174



530 Index

- electroconvulsive therapy (ECT) (*cont.*)
  - mild/moderate melancholia treatment, 230
  - and neurologic traits, 171–72
  - case studies, 171–72
  - outcomes, 181
  - characteristics, 715, 716
  - clinical criteria, 182
  - laboratory tests, 181
  - patient selection, 181–83
  - and personality disorders, 172
  - postpartum depression treatment, 36, 163–65
    - case studies, 164–65
  - post-stroke depression treatment, 258
  - and pregnancy, 163–65
  - psychosis studies, 25
  - psychotic depression treatment, 157–59, 223
    - case studies, 158–59
    - efficacy, 157, 158
  - relapse rates, 154, 188–89
  - remission rates, 181
    - age differences, 182
    - issues, 187–88
  - response issues, 182–83
  - risk factors, 183, 184
  - and schizophrenia treatment, 162
  - seizures
    - duration, 185
    - optimization, 185–86
  - side-effects, minimization, 101–84
  - stigmatization, 156, 174
  - and suicide prevention, 132
  - and suicide risk, 159–61
    - case studies, 160–61
  - technical issues, 183–90
  - training recommendations, 351–52
  - and transcranial magnetic stimulation
    - compared, 286–87
  - treatment frequency, 186–87
  - and treatment-resistant depression, 272–73
  - unipolar depression treatment, 172–74
  - vs antidepressants, 156, 157, 158, 161, 188–90
    - in pregnancy, 164
    - suicide risk, 159
  - vs pentylentetrazol, 154
  - see also* bilateral electroconvulsive therapy (BL-ECT); right unilateral electroconvulsive therapy (RUL-ECT)
- electroencephalography (EEG), 63
  - activated, 323–27
    - medication induction, 323
  - advantages, 320
  - arousal issues, 323
  - depressed patient studies, 321–23
  - drug effects, 322
  - early applications, 321
  - early studies, 321
  - in electroconvulsive therapy, 185–86
  - electrode placement issues, 322
  - and melancholia, 321
  - melancholia studies, 72–73
    - non-activated, 321
    - see also* sleep electroencephalography
  - electrophysiologic abnormalities, in melancholia, 320–27
  - electrophysiologic measures, and melancholia, 72–76
  - emotional incontinence, 116
  - emotional lability, 116
  - emotions
    - expressed, 358
    - processing, hemispheric differences, 329
    - regulation, 364
  - empirical approach
    - limitations, 52
    - to syndromes, 52
  - endocrinology, historical background, 62
  - endocrinopathies, and melancholia,
    - differential diagnosis, 111
  - endogenomorphic depression, 9
    - concept of, 67
  - endogenous depression, 8
    - use of term, 54
    - see also* melancholia
  - endophenotype, 331–32
  - England and Wales, suicide rates, 126
  - Enhancing Recovery in Coronary Heart Disease (ENRICH) trial, 263
  - environmental factors
    - genetically influenced, 303
    - interuterine, 304
    - in melancholia, 303–307, 332–33
    - and temperament, 302
  - epilepsy
    - case studies, 116–17
    - differential diagnosis, 116–17
    - electroencephalography, 321
    - with melancholia, pharmacotherapy, 260
  - epinephrine, isolation, 62
  - episodic memory, impairment, 327
  - eptapirone, 290
  - estrogen
    - effects on serotonin, 307, 313
    - and melancholia, 307
    - in melancholia treatment, 291
  - Euro-Americans, suicide rates, 125, 126
  - Europe, depression, prevalence, 50
  - examination (clinical) *see* clinical examination
  - excitatory amino acids, and melancholia, 316
  - exorcism, 3
  - expressed emotions, 358
  - facial expressions, and mood, 87
  - Falret, Jean Pierre, 18
    - on melancholia, 4
  - familial pure depressive disease, 19
  - family background, and suicide risk, 135–36
  - family studies, depressive mood disorders, 299–01
  - fathers, depressed, and genetic vulnerability, 305–306
  - Feighner criteria, 51
  - Feinberg, M., 75

531 Index

- fetus
  - circadian cycles, 356
  - drug safety issues, 239–40, 243
  - intrauterine stress responses, 304
  - malformations, 240–41
  - sleep and, 356–57
- Fink, Max, 7–8
- Finland
  - depression studies, 354–55
  - electroconvulsive therapy, and suicide risk, 159–60
- firearms
  - access removal, 145
  - and suicide, 125–26, 133, 137
  - case studies, 133
- fluoxetine
  - and breast-feeding, 243
  - drug–drug interactions, 265
  - effectiveness, 202–203, 204
    - adolescents, 249
    - children, 248
    - elderly, 253
  - effects on suicide rates, 140, 141
  - heart disease with melancholia
    - treatment, 263
  - neonatal issues, 241
  - and placebo response, 201
  - post-stroke depression treatment, 258
  - side-effects, 205
  - studies, 202
- flupenthixol, effects on suicide rates, 140
- fluvoxamine
  - drug–drug interactions, 265
  - effects on suicide rates, 141
- folate deficiency, and depression risk, 111
- folic acid, in pregnancy, 242
- follow-up studies, inadequate, and suicide risk, 132–33
- France
  - antidepressants, prescription increases, 50
  - electroconvulsive therapy studies, 166–67
- Freemantle, N., 199–200
- Freud, Sigmund, melancholia theories, 6
- frontal lobe disease
  - differential diagnosis, 113–14, 814
  - symptoms, 113–14
- GABAergic agents, 290
- GAF (Global Assessment of Function), 202
- Galen, 3
- Ganser syndrome, and psychotic depression, 30
- Geddes, J., 203
- genetic factors
  - alcoholism, 255
  - and depression risk, 543
  - depressive mood disorders, 255
  - manic-depressive illness, 330
  - melancholia, 298, 299–203,  
331–32, 361
  - temperament, 332
  - see also* heritability
- genetic vulnerability, 299–201, 331–32
  - depressed fathers, 305–306
  - depressed mothers, 305–306
    - mechanisms, 362
- gepirone, 290
- geriatric depression, 9
- Geriatric Depression Scale, 94
- Germany, St. John’s wort studies, 293
- Glasgow Depression Scale, 94
- Global Assessment of Function (GAF), 202
- glucocorticoid receptors (GRs)
  - abnormal functioning, 311
  - antidepressant effects, 311
  - cortisol resistance, 311
  - reduced, 310–11
  - type I, 308
  - type II, 308
- glucocorticoids
  - adaptive effects, 308–309
  - animal studies, 308
  - overexposure effects, 309
  - roles, 308
  - synthetic, 64
- glucocorticosteroid receptor agonists, in melancholia treatment, 289–90
- glucose metabolism
  - and antidepressants, 226
  - decrease, 319
  - elevated, 318–19
  - and sleep, 325
- glutamate NMDA, 290
- glutamate signaling modifiers, 363
- Goodwin, F. K., 19–20
  - on antidepressant-induced mania, 22
- G-protein, 362
- Greenblatt, M., 156
- GRs *see* glucocorticoid receptors (GRs)
- Gunnell, D., 141–42
- guns *see* firearms
- Hadzi-Pavlovic, D., 25–26, 53
- hallucinations, 89
- haloperidol, with amitriptyline, 224
- HAMD *see* Hamilton Rating Scale for Depression (HRSD)
- Hamilton Rating Scale for Depression (HRSD), 91–93, 137, 171
  - applications, 94–95
  - in electroconvulsive therapy studies, 158, 160, 165, 171
  - limitations, 92
  - shorter versions, 93, 847
- Harris, Geoffrey, 62
- Haslam, John, on melancholia, 4
- HD *see* Huntington’s disease (HD)
- health professionals
  - accreditation, 351
  - education
    - electroconvulsive therapy training, 351–52
  - in mood disorders, 351–52
- heart disease
  - with melancholia
  - mortality rates, 262

532 Index

- heart disease (*cont.*)
  - pharmacotherapy, 262–64
  - see also* cardiovascular disease
- heart failure, risks, 262
- hemispheres
  - emotion-processing, 329
  - specialization, approach–withdrawal theories, 322
- hemispheric instability, and manic-depressive illness, 329–30
- hemispheric sleep phase coherence, 326
- sex differences, 326
- herbal remedies, for melancholia, 292–94
- heritability
  - estimates, 300
  - melancholia, 346
  - neurogenesis, 363
  - and temperament, 302
  - see also* genetic factors
- Hickie, I., 202
- Hill, Sir John Denis Nelson, 5–6
- hippocampus, neurogenesis, 363
- Hippocrates, on melancholia, 2–3
- histrionic personality disorder, 98
- Hoch, August, case studies, 32
- homeostatic functions, perturbations, 88–89
- HOPA gene, polymorphisms, 362
- Hopewell-Ash, Edwin Lancelot
  - on melancholia, 5
  - Melancholia in Everyday Practice* (1934), 16, 17
- hormonal changes
  - during pregnancy, 33
  - and puerperal psychosis, 36
- hormones
  - imbalance, 111
  - and melancholia, 306–307
  - in melancholia treatment, 291–92
  - systemic effects, 63
  - therapeutic replacement, 62
  - see also* adrenocorticotrophic hormone (ACTH); corticotropin-releasing hormone (CRH); thyroid-stimulating hormone (TSH); thyrotropin-releasing hormone (TRH)
- hospitalization
  - failure
    - case studies, 133
    - and suicide risk, 133–34
  - suicidal melancholic patients, 143–45
  - guidelines, 143
  - indications, 143
  - and suicide risk, 135, 143–44
- HPA axis *see* hypothalamic–pituitary–adrenal (HPA) axis
- HPGH (hypothalamic–pituitary–growth hormone) system, 63
- HPT axis *see* hypothalamic–pituitary–thyroid (HPT) axis
- HRSD *see* Hamilton Rating Scale for Depression (HRSD)
- 5-HT<sub>1A</sub> (5-β-hydroxytryptamine receptor 1) agonists, 290
- 5-HT<sub>2A</sub> receptor gene, 359–60
- 5-HT *see* serotonin
- 5-HTT gene, 303
- Huntington’s disease (HD)
  - differential diagnosis, 115–16
  - with melancholia, pharmacotherapy, 259–60
- Huston, P. E., 155
- 17-hydroxycorticosteroids, and mood disorders, 64
- 5-hydroxytryptamine (5-HT) *see* serotonin
- 5-β-hydroxytryptamine receptor 1 (5-HT<sub>1A</sub>) agonists, 290
- 5-hydroxytryptamine receptors, 5HT<sub>1A</sub>, 310–11
- hyperadrenalism, and insomnia, 62
- hypercortisolemia, 64
  - as depression marker, 66, 77
- hyperglycemia, 264
- hypericum, in melancholia treatment, 292–93
- hyperparathyroidism
  - differential diagnosis, 111
  - etiology, 111
- hypnotics, and fetal safety, 239–40
- hypomania, 21
- hypothalamic hormones, in electroconvulsive therapy evaluation, 186
- hypothalamic–pituitary–adrenal (HPA) axis, 63
  - abnormalities, 298
  - diagnostic issues, 66–67, 78
  - hyperactivity, 219
  - and melancholia, 64–72
  - overactivity, 364
  - and stress response, 307–308, 363
  - mechanisms, 311
  - suppression, 65
  - targeting, 363
  - use of term, 64
- hypothalamic–pituitary–growth hormone (HPGH) system, 63
- hypothalamic–pituitary–thyroid (HPT) axis, 63
  - evaluation, 72
  - functions, 72
  - and melancholia, 72
- hypothalamus
  - as biological clock, 356
  - and stress responses, 309
- hypothyroidism
  - comorbidity, 72
  - with melancholia, pharmacotherapy, 265
- hysteroid dysphoria, 98–99
- ICD-8 *see* International Classification of Diseases (ICD-8)
- ICD-10 *see* International Classification of Diseases (ICD-10)
- id, 6
- imipramine, 50
  - drug-switching, 214
  - effectiveness
    - alcoholics, 255
    - children, 246, 247, 248

533 Index

- effects on electroconvulsive therapy, 188–89
- and electroconvulsive therapy compared, 157
- manic-depressive illness treatment, 227
- melancholia treatment, 211
- mood disorder treatment studies, 7–8
- psychosis studies, 25
- severe melancholia treatment, 230
- immune response system, and melancholia, 363–64
- implicit memory, 327
- inflammatory markers
  - abnormalities, 63
  - and depression, 63
- inflammatory response, 363–64
- inpatient care, suicidal melancholic patients, 143–45
- insanity
  - circular, 4
  - classification, 3–4
- insomnia, and hyperadrenalism, 62
- insulin, discovery, 62
- insulin coma, 6–7
  - treatment, 62
- International Classification of Diseases (ICD-8), 55
  - psychotic disorders, 106
  - reliability issues, 8
- International Classification of Diseases (ICD-10)
  - limitations, 2
  - melancholia, 26
- interpersonal therapy, in depression
  - treatment, 218
- inter-rater reliability, 200
- interuterine factors, 304
- involuntary commitment
  - and suicide risk, 133–34
  - case studies, 133
- involutional depression, 9
- iproniazid, 50
- irritable depression, 54
- Jamison, K. R., 19–20
  - on antidepressant-induced mania, 22
- Japan, depression, epidemic, 50–51
- Johns Hopkins Hospital (USA), Henry Phipps Psychiatric Clinic, 154–55
- Journal of the American Medical Association, The*, 198
- Kahlbaum, Karl, 18
  - catatonia
    - case studies, 30–31
    - research, 30
- Kalinowsky, L. B., 155
- kava, side-effects, 294
- Kayser–Fleischer rings, 116
- Kendell, R. E., 53
  - on structured interviews, 85
  - two depression factors, 53, 54–55
- Kendler, K. S., 27, 300
- ketoconazole, in melancholia
  - treatment, 290
- Kirsch, I., 199
- Klein, D. F., 7–8, 98–99
- Kleinman, Arthur, 51
- Kraepelin, Emil
  - on manic-depressive illness, 18–19
  - melancholia theories, 4–5
  - criticisms, 6
- laboratory tests, and melancholia
  - defined, 62–78
- lamotrigine, 225, 290
  - manic-depressive illness treatment, 229
  - severe melancholia treatment, 230
- late-life depression *see* vascular depression
- laughing, pathological, 116
- left hippocampal cortex, reduced metabolism, 319
- Leonhard, Karl, 23
  - manic-depressive illness theories, 19
- lesopitron, 290
- leucotomy, 6–7
- Levinson, D. F., 300
- Lewis, Aubrey, on melancholia, 5
- lidocaine, effects on seizure, 188
- light therapy (LT), 362
  - dawn simulation, 285
  - melancholia, 284–85
- Linnaeus, Carolus, 1
- lithium, 50
  - effects on electroconvulsive therapy, 189
  - effects on suicide rates, 139–40
  - efficacy, 23, 24
  - in electroconvulsive therapy, 188, 189–90
  - manic-depressive illness treatment, 227
  - in melancholia treatment, 211
  - mild/moderate melancholia treatment, 230
  - neonatal issues, 242
  - severe melancholia treatment, 230
- lithium augmentation, 215–16
  - dose–response characteristics, 215
  - effectiveness, 215–16
  - in melancholia treatment, 220–21
  - side-effects, 216
- Locher, L. M., 155
- Loewi, Otto, 62
- London, Bethlem Hospital, 4
- lorazepam
  - in catatonia diagnosis, 31
  - in catatonia treatment, 225
- LT *see* light therapy (LT)
- lupus erythematosus, and depressive mood disorders, 111
- Lyme disease, and depression, 111
- MADRS (Montgomery–Asberg Depression Rating Scale), 93
- magnetic resonance imaging (MRI)
  - in catatonia diagnosis, 31
  - cerebrovascular disease studies, 105
  - in epilepsy studies, 117
- magnetic seizure therapy (MST)
  - in melancholia treatment, 288
  - safety issues, 288

Cambridge University Press

978-0-521-13124-7 - Melancholia: The Diagnosis, Pathophysiology, and Treatment of Depressive Illness

Michael Alan Taylor and Max Fink

Index

[More information](#)

- major depression, 3, 9
  - case studies, 48–49
  - comorbidity, 301
  - diagnostic criteria, 8, 18, 48–49
  - non-melancholic, 97
  - differential diagnosis, 99–00
  - treatment, issues, 51
- major depression superimposed upon
  - delusional disorder, 46
  - see also* schizophrenia
- major depressive disorder, 9
  - studies, 21
- malarial fevers, 6–7
- males, over 50 years of age, suicide risk, 136–37
- malignant catatonia (MC), electroconvulsive therapy, 161
- mania
  - antidepressant-induced, 22–23
  - incidence, 22
  - classification issues, 347
  - and depression, 4, 18
  - early studies, 19
  - and insanity, 3–4
  - Kraepelin's theories, 5
  - use of term, 4
- manic depression, 4
  - case studies, 32
  - and Cotard syndrome, 29
- manic-depressive illness, 18–24, 46
  - adolescents, 245
  - antidepressant treatment, 226–27
  - and cerebral hemispheric instability, 329–30
  - children, 245
  - convulsive therapy, early studies, 153–54
  - and dementia praecox compared, 18–19
  - early studies, 173
  - electroconvulsive therapy, 172–74
  - genetic factors, 330
  - neurobiologic markers, 328
  - pharmacotherapy, 225
    - mood switch risk, 225–26
  - and recurrent depressive illness, 23, 301
  - sensitization model, 328
  - singularity, 21
  - suicide in, 136
  - theories
    - Kraepelin's, 18–19
    - Leonhard's, 19
    - twin studies, 330
    - see also* bipolar disorders
- manic episodes, in melancholia, 299, 328–30
- manisch-depressive Irresein*, 4
- MAOIs *see* monoamine oxidase inhibitors (MAOIs)
- maprotiline, epilepsy with melancholia
  - treatment, 260
- marital conflict, effects on children, 306
- maternal care, 305–306
- Maudsley Hospital (UK), 53
- Mayo Clinic (USA), electroconvulsive therapy
  - studies, 166
- MC (malignant catatonia), 161
- Mecholyl (methacholine) test, 181
- Medicaid (USA), 270
- medical illness
  - and melancholia, 110–12
  - with melancholia, pharmacotherapy, 261–65
  - and suicide risk, 137–38
- medical practitioners *see* health professionals
- medications *see* drugs
- Medline
  - melancholia citations, 47
  - trials data, 350
- Meduna, Ladislav, 153
- melancholia
  - and abnormal bereavement, 36–37, 46, 97
  - abnormal brain metabolism, 318–20, 332, 343
  - abnormal brain structure, 317–18, 329, 346
  - abnormal neurochemical functioning, 311–17
  - in adolescents, 103–104
    - pharmacotherapy, 244–50
    - recommendations, 250
  - with agitation, suicide risk assessment, 135–36
  - and alcohol abuse, 108–109
    - pharmacotherapy, 155–55, 256
  - with anxiety, suicide risk assessment, 135–36
  - with Asperger syndrome, 104
  - with autism, 104
  - behavioral characteristics, Table 3.4
  - biological studies, issues, 299
  - case studies, 16–18
    - early, 16, 17
  - and catatonia, 30, 32, 97
  - characteristics, 15–16, 982, 346, 348
  - and childhood stress, 306
  - in children, 103–104
    - pharmacotherapy, 244–50
    - prevention, 354–58
    - recommendations, 250
  - and circadian cycles, 310
  - classification, 16
  - future trends, 346–49
  - issues, 45
  - simplified, 348
  - clinical examination, 85–95
    - strategies, 86–87, 446
  - and cognition, 90–91
  - cognitive deficits, 327–28
    - studies, 327–28
  - comorbidity
    - children and adolescents, 91–93, 103
    - elderly, 105
  - concept of, 5
  - criticisms, 53
  - distinct, 51, 58
  - origins, 2–9
  - conceptual history, 9
  - convulsive therapy, 346
  - criteria, and psychotic depression, 27–29
  - defined, 15–37
    - by laboratory tests, 62–78
    - by psychopathology, 59
    - by specific event, 32–36
  - definitions, 15, 97
  - early, 15

535 Index

- as depressive disorder, 45, 58
- diagnostic criteria, 62–78, 298
  - future trends, 348–49
  - proposals, 348–49
- diagnostic issues, 155
- differential diagnosis, 58, 97–18
- and dopamine dysfunction, 315
- and drug abuse, pharmacotherapy, 255, 256
- and drug-related depressive-like states, 109–10
- early studies, 5
- in elderly, 104–106
  - case studies, 253–54
  - pharmacotherapy, 250–54
  - recommendations, 254
- electroconvulsive therapy, 174, 221
  - case studies, 157
  - effectiveness, 155–57, 211
  - issues, 174
  - outcomes, 181
- and electroencephalography, 321
- electroencephalography studies, 72–73
- electrophysiologic abnormalities, 320–27
- electrophysiologic measures, 72–76
- environmental factors, 303–307, 332–33
  - genetically influenced, 303
- and estrogen, 307
- and excitatory amino acids, 316
- first episode, 358
- future trends, 365
- genetic factors, 298, 299–03,
  - 331–32, 361
- vulnerability, 299–01
- glucocorticosteroid receptor agonist treatment, 289–90
- herbal remedies, 292–94
- heritability, 346
- historical perceptions, 45–46
- histories, 2
- and hormones, 306–307
- hormone therapy, 291–92
- and hypothalamic–pituitary–adrenal axis, 64–72
- and hypothalamic–pituitary–thyroid axis, 72
- and immune response system, 363–64
- and insanity, 3–4
- involutional, 4
- light therapy, 284–85
- magnetic seizure therapy, 288
- manic episodes, 299, 328–30
- with medical illness, 110–12
  - pharmacotherapy, 261–65
- Medline citations, 47
- motor issues, 25–26
- nature of, 56–57
- neuroendocrine tests, 77–78
- with neurologic diseases, pharmacotherapy, 257–61
- and neuropeptides, 316–17
- and neurotrophic abnormalities, 316
- and noradrenergic dysfunction, 313–14
- observable features, 441
- and pain, 112
- paradigms, 58–59
- pathophysiology, 298–33
  - future trends, 360–64
- with personality disorders, pharmacotherapy, 265–66
- and personality traits, 91
- pharmacotherapy, 220–22, 346
  - acute treatment, 220–21
  - drug–drug interactions, 265, 650
  - drug-switching, 221
  - historical background, 196
  - inpatient vs outpatient settings, 212
  - long-term treatment, 211, 221–22
  - randomized controlled trials, 196
  - treatment recommendations, 229–30
- pharmacotherapy literature, validity, 196–07
- postmortem studies, 310, 317–18
- in pregnancy
  - case studies, 240
  - neonatal issues, 241–42
  - pharmacotherapy, 239–44
  - prevention, 355–56
- prevalence
  - children and adolescents, 103
  - elderly, 104–105
  - early, 354–58
  - future, 354–58
  - and sleep, 356–57
- and pseudodementia, 90
- in psychiatric classification, 7–9
- and psychomotor disturbance, 55, 57, 88
- psychopathological validity, 53–56
  - post-1980 literature, 54–56
  - pre-1980 literature, 53–54
- and psychosis, 16, 55
- and psychotherapy, 218–19
- and psychotic depression, 24–30, 97
- with psychotic disorders, 106–108
  - suicide risk assessment, 135–36
- and puerperal depression, 36, 97
- recognition, 348
- remission, 181
  - goals, 349–50
- reviews, 2
- and schizophrenia, differential diagnosis, 106–108
- and serotonin dysfunction, 312–13
- and sleep apnea, 112, 269
- and sleep disturbances, 269
- sleep electroencephalography studies, 73–76, 325–26
- stress responses
  - abnormal, 307–11
  - genetically influenced, 303
  - mechanisms, 311
- subtypes, 97
- suicide in, 125–45
- as syndrome, 58
- targeted neurotransmitter system agent treatment, 290
- temperamental risk factors, 302
- theories

536 Index

- melancholia (*cont.*)
  - Freud's, 6
  - Kraepelin's, 4–5
  - transcranial magnetic stimulation, 286–88
  - treatment
    - algorithms, 348, 364–65
    - options, 346
    - proposals, 284–94
    - treatment trials, recommendations, 350
  - tricyclic antidepressant treatment, 206–207
  - and triiodothyronine, 307
  - use of term, 1, 4
    - advantages, 2, 16
    - historical background, 45
    - Meyer's views, 6
  - vagal nerve stimulation, 289
  - vs psychodynamic theories, 6–7
  - see also* depression; endogenous depression;  
mild/moderate melancholia; severe melancholia
- melancholia with psychosis *see* psychotic depression
- melancholic patients
  - cognitive deficits, 327–28
  - compliance issues, 358
  - memory deficits, 327
  - pharmacotherapy, 211–30
    - acute treatment, 211–19
    - augmentation limitation, 214–15
    - continuation treatment, 211, 219–20, 254
    - drug-switching trials, 214–15
    - issues, 211
    - lithium augmentation, 215–16
    - maintenance treatment, 219–20, 254
    - with psychotherapy, 218–19
    - rapid response, 212–14
    - recommendations, 266–68
    - relapse rates, 219–20
    - treatment recommendations, 229–30
    - treatment resistance, 212–13
  - psychotherapy, with pharmacotherapy, 218–19
  - see also* depressed patients; suicidal melancholic patients
- melancholy, definitions, 15
- memory deficits, melancholic patients, 327
- men, over 50 years of age, suicide risk, 136–37
- Mendel, Gregor Johann, 1
- mental disorders
  - natural vs unnatural, 3
  - and witchcraft, 3
- metabolism
  - stress effects on, 62–63
  - see also* brain metabolism; drug metabolism; glucose metabolism
- methacholine test, 181
- N-methyl-D-aspartate (NMDA), 363
  - binding, 316
- methylphenidate, drug augmentation, 216
- Metrazol *see* pentylenetetrazol
- Mexicans, suicide rates, 126
- Meyer, Adolf, 16
  - on depressive disorders, 6
- mianserin, effects on suicide rates, 140
- mice, stress response studies, 303
- mifepristone, in melancholia treatment, 289–90
- mild depression, 51, 54
- mild/moderate melancholia
  - electroconvulsive therapy, 230
  - treatment recommendations, 229–30
- Miller, F. T., 202
- Mini-Mental State Examination (MMSE), 91, 252
- minor depression, 46
  - classification issues, 347–48
  - differential diagnosis, 101
- mirtazapine
  - effectiveness, 204
  - melancholia treatment, 211
  - overdose, 142
- MMSE (Mini-Mental State Examination), 91, 252
- moclobemide, 290
  - effectiveness, elderly, 254
  - manic-depressive illness treatment, 227
- monoamine deficit theory, 312
- monoamine oxidase inhibitors (MAOIs)
  - approved, 50
  - atypical depression treatment, 99
  - drug augmentation, 217
  - effectiveness, 202
    - children and adolescents, 249
    - elderly, 254
  - and electroconvulsive therapy compared, 156
  - mania induction, 22
  - manic-depressive illness treatment, 226
  - overdose, lethality, 142–43
- Montgomery–Asberg Depression Rating Scale (MADRS), 93
- mood
  - clinical examination, 87
  - and facial expressions, 87
  - screening questions, 87
  - and sleep deprivation, 326–27
- mood-congruence, of psychotic thoughts, 26–27
- mood-congruent delusions, 26–27
- mood disorder due to a general medical condition, 46
- mood disorders
  - classification, 1–2, 9, 18
  - by treatment, 5–6
  - issues, 347, 365
  - simplification, 9
  - convulsive therapy, 154
  - diagnostic criteria, 8
  - dichotomy issues, 21
  - drug-induced, 655
  - health professional education, 351–52
  - neuroendocrine tests, 62–63
  - not otherwise specified, 46
  - pregnancy-related, 33–36
  - psychotic, 25
  - sensory evoked potentials studies, 324



537 Index

- treatment, early, 357–58
  - see also* adjustment disorder with depressed mood; depressive mood disorders; puerperal mood disorders
- mood-incongruent delusions, 26–27
  - as mood disorders, 27
  - reviews, 27
  - studies, 27
- mood quality, and melancholia, 348
- mood stabilizers, 23, 227–29
  - drug–drug interactions, 265
  - neonatal issues, 242–43
  - severe melancholia treatment, 230
- mothers
  - psychotic, studies, 354
  - see also* depressed mothers
- MRI *see* magnetic resonance imaging (MRI)
- MST *see* magnetic seizure therapy (MST)
- multiple sclerosis (MS), and depressive mood disorders, 116
- Myerson, A., 154
- myxedema, 62
- naltrexone, in alcoholism treatment, 255
- National Comorbidity Survey (USA), 300
- National Institute of Mental Health (NIMH) (USA)
  - antidepressant guidelines, 196
  - depression studies, 56–57
  - electroconvulsive therapy studies, 173
  - and STEP-BD algorithm, 23
- NE *see* norepinephrine (NE)
- NEDDI (Newcastle Endogenous Depression Diagnostic Index), 94
- nefazodone
  - effectiveness, 205, 224
  - side-effects, 205–206
- Nelson, J. C., 57
- neonates
  - issues, 241–42
  - premature, 304
  - risk factors, 304
- Netherlands, The, depression studies, 55
- neurobiologic markers, of manic-depressive illness, 328
- neurochemical functioning, abnormal, in melancholia, 311–17
- neurocognitive abnormalities, 26
- neuroendocrine abnormalities, 26
  - as markers
  - limitations, 63
  - re-examination, 63
  - and sleep electroencephalography studies, 63
- neuroendocrine hypothesis, 353
- neuroendocrine tests, 24
  - advantages, 77–78
  - as melancholia indices, 348
  - in mood disorders, 62–63
- neuroendocrine variables, and sleep variables, 74–75
- neurogenesis
  - heritability, 363
  - in hippocampus, 363
- neurohumoral theory, 353–54
- neuroleptic malignant syndrome (NMS)
  - differential diagnosis, 161–62
  - electroconvulsive therapy, 162
- neurologic diseases
  - and apathetic syndromes, 113–18
  - and depression-like syndromes, 113–18
  - with melancholia, pharmacotherapy, 257–61
- neurologic illness, and suicide risk, 137–38
- neurologic traits
  - and electroconvulsive therapy, 171–72
  - case studies, 171–72
- neuropeptides, and melancholia, 316–17
- neuropeptide Y, roles, 317
- neurophysiologic hypotheses, 353
- neuroplasticity
  - abnormal, animal studies, 314–15
  - enhancement, 362–63
  - impairment, 362
- neurosyphilis, 1
- neurotic depression, 8
  - Kendell’s studies, 53
- neurotoxic effects
  - prevention, 363
  - reduction, 362–63
- neurotrophic abnormalities, and melancholia, 316
- newborn *see* neonates
- Newcastle Endogenous Depression Diagnostic Index (NEDDI), 94
- New England Journal of Medicine, The*, 198
- New Jersey Medicare (USA), 224
- New York City (USA)
  - electroconvulsive therapy
  - services, 351–52
  - studies, 187
- nicotine, and depressive mood disorders, 256
- NIMH *see* National Institute of Mental Health (NIMH) (USA)
- NMDA *see* N-methyl-D-aspartate (NMDA)
- NMS *see* neuroleptic malignant syndrome (NMS)
- non-melancholic depression, 54
  - diagnostic criteria, 25–26
  - differential diagnosis, 98–03
- non-psychotic depression, differential diagnosis, 26
- non-psychotic melancholia, diagnostic criteria, 25–26
- non-tricyclic antidepressants, vs selective serotonin reuptake inhibitors, 204–206
- noradrenergic agents, 290
- noradrenergic dysfunction
  - animal studies, 314
  - and melancholia, 313–14
- norepinephrine (NE)
  - dysfunction, and melancholia, 313–14
  - effects on glucocorticoid receptor
  - functioning, 311
  - function, in depressive mood disorders, 313–14
- norepinephrine–serotonin interactions, 314–15
- nortriptyline
  - comparative studies, 199–00

538 Index

- nortriptyline (*cont.*)
  - effectiveness, 203, 204, 313
  - children, 246
  - elderly, 251, 252, 253
  - effects on electroconvulsive therapy, 189
  - in electroconvulsive therapy, 189–90
  - heart disease with melancholia
    - treatment, 262–63, 264
  - in melancholia treatment, 211, 221
  - with perphenazine, 224
  - post-stroke depression treatment, 258
  - studies, 202
- NREM sleep
  - and glucose metabolism, 325
  - studies, 76
- obsessive-compulsive disorder (OCD), differential diagnosis, 108
- olanzapine, 225
  - drug augmentation, 217
  - drug–drug interactions, 265
  - Huntington’s disease with melancholia
    - treatment, 260
    - side-effects, 223–24
- olanzapine-fluoxetine, 23
- omega-3 fatty acids, in melancholia
  - treatment, 293
- oneiroid states, 107
- oneirophrenia, 34
- orbital cortex, volume reduction, 318
- organic solvent abuse, and melancholia,
  - differential diagnosis, 110
- Othello syndrome, and psychotic depression, 30
- outpatients
  - inadequate follow-up
    - case studies, 133
    - and suicide risk, 132–33
  - suicidal melancholic patients, 144–45
- over-the-counter drugs, and melancholia,
  - differential diagnosis, 110
- pain, and melancholia, 112
- pancreatic carcinoma, and depression, 111
- parenting issues, 305–306
- Parker, G., 25–26, 53, 68, 199, 202
- Parkinson’s disease (PD)
  - comorbidity, 115
  - and dexamethasone suppression test, 115
  - differential diagnosis, 115
  - with melancholia, pharmacotherapy, 258–59
- paroxetine
  - drug–drug interactions, 250
  - effectiveness, 203
  - adolescents, 248
  - children, 248
  - effects on electroconvulsive therapy, 188–89
  - effects on suicide rates, 140, 141
  - studies, 141
  - heart disease with melancholia treatment,
    - 262–63, 264
  - Parkinson’s disease with melancholia
    - treatment, 259
    - severe melancholia treatment, 230
    - side-effects, 205
- paternal modulation, 305–306
- pathological mood, definition, 15
- patient non-compliance, 220
  - prevention strategies, 358
- patient selection, for electroconvulsive therapy,
  - 181–83
- Paxil, usage, 50–51
- Paykel, E. S., 53–54
- pCREB (phosphorylated cyclic AMP response element-binding protein), 360
- PD *see* Parkinson’s disease (PD)
- PDD *see* premenstrual dysphoric disorder (PDD)
- pentylene-tetrazol, 153
  - affective disorder treatment, 155
  - early studies, 153–55
  - seizure induction, 161
  - vs electroconvulsive therapy, 154
- perphenazine, with nortriptyline, 224
- Perris, C., 23
- personality disorders
  - borderline, 99
  - clinical examination, 91
  - and depression diagnosis, 55–56
  - dramatic-emotional, 109
  - and electroconvulsive therapy, 172
  - histrionic, 98
  - with melancholia, pharmacotherapy, 265–66
  - premorbid, 265–66
- personality traits
  - and melancholia, 91
  - see also* temperament
- pharmaceutical industry
  - conflict-of-interest issues, 198
  - recommendations, 350–51
  - influences, and novel antidepressants, 197–99
  - and sponsor roles, 198
  - treatment efficacy standards, 199
  - recommendations, 350–51
- pharmacogenetics, future trends, 359–60
- pharmacotherapy
  - future research standards, 349–51
  - inadequate
    - case studies, 132
    - and suicide risk, 132, 141
  - for melancholic patients, 211–30
  - in complicating circumstances, 465
  - with psychotherapy, 218–19
- pharmacotherapy literature, in melancholia,
  - validity, 196–07
- phenelzine, 50
  - effectiveness, children and adolescents, 249
- phenytoin, drug–drug interactions, 265
- phosphorylated cyclic AMP response element-binding protein (pCREB), 360
- pindolol, drug augmentation, 216
- pituitary gland, hypothalamic control, 62
- PKA (protein kinase A), 360
- Plutarch, on melancholia, 3
- post-concussion syndrome, symptoms, 115
- posterior orbital cortex, increased metabolism,
  - 319–20

539 Index

- posterior ventrolateral prefrontal cortex, volume reduction, 318
- postpartum blues, 33
- postpartum depression, 9, 46
  - antidepressant treatment, 163
  - electroconvulsive therapy, 36, 163–65
    - case studies, 164–65
  - incidence, 33
  - light therapy, 285
  - and melancholia, 46
  - pharmacotherapy, 243
  - psychotherapy, 243
  - risk factors, 35–36
  - treatment outcomes, 36
- postpartum non-psychotic melancholia, definition, 34
- post-psychotic depression, 46
  - diagnostic criteria, 106
- post-schizophrenia depression, diagnostic criteria, 106
- post-stroke depression
  - pharmacotherapy, 257–58
- post-traumatic stress disorder (PTSD), case studies, 130
- prednisolone, 64
- pregnancy
  - and electroconvulsive therapy, 163–65
    - fetal monitoring, 164
  - vs antidepressants, 164
  - hormonal changes, 33
  - melancholia in
    - case studies, 240
    - neonatal issues, 241–42
    - pharmacotherapy, 239–44
    - prevention, 355–56
    - treatment-withholding effects, 240
  - and mood disorders, 33–36
- premature births, 304
- premenstrual dysphoric disorder (PDD), 46
  - comorbidity, 102
  - differential diagnosis, 102–103
  - etiology, 102
  - inheritance, 102
  - treatment, 103
  - twin studies, 102
- prepartum depression
  - light therapy, 285
  - psychotherapy, 243
  - risks, 240
- prescription drugs, and melancholia, differential diagnosis, 110
- Preskorn, S. H., 202
- procyclidine, mood disorder treatment studies, 7–8
- progesterone
  - decrease, 36
  - effects on serotonin, 313
  - in melancholia treatment, 291–92
- protein kinase A (PKA), responses, 360
- Protheroe, C., 34
- protriptyline, melancholia treatment, 211
- pseudodementia
  - and Alzheimer's disease, 261
  - differential diagnosis, 118, 158
  - and melancholia, 90
  - use of term, 90
- Psychiatric Annals*, 2
- psychiatric disorders
  - causes, single vs many, 4
  - diagnostic issues, 62
- psychoactive drugs
  - drug–drug interactions, 265
  - studies, 197
- psychodynamic theories, vs melancholia, 6–7
- psychoeducation, 23
  - see also psychotherapy
- psychological autopsies, 126
- psychomotor disturbance
  - definition, 16
  - factors, 57
  - and melancholia, 55, 57, 88, 348
- psychomotor functioning, clinical examination, 88
- psychomotor retardation, 53, 55, 57
- psychopathology
  - and melancholia
  - defined, 59
  - validity, 53–56
- psychosis, 8
  - case studies, 32
  - detection issues, 26
  - diagnostic criteria, 25
  - and melancholia, 16, 55, 348
  - and schizophrenia, 25
  - see also puerperal psychosis
- psychotherapy
  - adolescents, 244–45
  - children, 244–45
  - effects on suicide rates, 140
  - and melancholia, 218–19
  - with pharmacotherapy, 218–19
  - postpartum depression, 243
  - prepartum depression, 243
  - psychoeducation, 23
- psychotic depression, 8, 46, 54
  - antidepressant/antipsychotic treatment, 223–24
  - case studies, 28–29, 89–90, 223
  - classification issues, 347
  - comorbidity, 30
  - and Cotard syndrome, 29–30
  - diagnostic criteria, 25–26
  - differential diagnosis, 26, 97–08
  - electroconvulsive therapy, 157–59, 223
    - case studies, 158–59
  - efficacy, 157, 158
  - historical background, 24–26
  - Kendell's studies, 53
  - and melancholia, 24–30, 97
    - criteria, 27–29
  - mortality rates, 222
  - pharmacotherapy, 222–23
  - relapse rates, 26
  - studies, 26
  - suicide rates, 223
  - and suicide risk, 89
  - treatment, 108

540 Index

- psychotic disorders
  - classification, 106
  - issues, 25
  - clinical examination, 89–90
  - diagnostic criteria, 25
  - with melancholia, 106–108
  - suicide risk assessment, 135–36
  - prevention, 354
- psychotic mood disorder, classification
  - issues, 25
- psychotic thoughts, mood-congruence, 26–27
- psychotropic drugs
  - and breast-feeding, 243–44
  - and fetal safety, 239–40, 243
- PTSD (post-traumatic stress disorder), 243
- puberty, biological differences, 245–46
- puerperal depression, 33–36
  - case studies, 34
  - classification issues, 35, 206
  - incidence, 35
  - and melancholia, 36, 97
- puerperal mood disorders
  - and melancholia, 36
  - prevention, 357
- puerperal psychosis, 34
  - and hormonal changes, 36
- puerperal psychotic depression, diagnostic criteria, 33–34
- Puerto Ricans, suicide rates, 126
- quetiapine, 224
- Quitkin, F. M., 98–99
- R121919, 363
- rapid cycling, 8–9
- rating scales, 91
  - applications, 94–95
  - of depression, 91–95
  - and diagnostic criteria, 85
  - limitations, 85–86
- RDC *see* Research Diagnostic Criteria (RDC)
- reactive depression, 3, 8
- recurrent depressive illness, and manic-depressive illness, 23, 301
- remacemide, 290
- REM latency, 73, 205
  - as depression marker, 74, 325
  - shortened, 326
  - and suicide risk, 138
- Research Diagnostic Criteria (RDC), 8, 51
  - depression studies, 55
- retardation
  - and melancholia, 45–46
  - psychomotor, 53, 55, 57
  - symptoms, 16
- reward mechanisms
  - and depressive mood disorders, 315
  - potentiation, 315
- rheumatoid arthritis, and depression risk, 111
- right unilateral electroconvulsive therapy (RUL-ECT), 184
  - and bilateral electroconvulsive therapy compared, 184
  - disadvantages, 184
  - energy dosing, 186
- risperidone
  - drug augmentation, 217
  - drug–drug interactions, 265
  - effectiveness, 224
- risperidone/fluvoxamine, 217
- Rotterdam (Netherlands), 35
- RU486 (mifepristone), 289–90
- RUL-ECT *see* right unilateral electroconvulsive therapy (RUL-ECT)
- Rush, A. J., 57
- SAD *see* seasonal affective disorder (SAD)
- SADHEART (Sertraline Antidepressant Heart Attack Randomized Trial), 263–64
- SADS *see* Schedule for Affective Disorders and Schizophrenia (SADS)
- St. John's wort
  - in melancholia treatment, 292–93
  - side-effects, 293
- Schedule for Affective Disorders and Schizophrenia (SADS), 50
  - depression studies, 55, 56–57
- schizoaffective disorders, 25
- schizophrenia, 46
  - and dexamethasone suppression test, 107–108
  - diagnostic criteria, 25
  - early studies, 24–25
  - and electroconvulsive therapy, 162
  - and melancholia, differential diagnosis, 106–108
  - and psychosis, 25
  - symptoms, 106–107
  - transatlantic differences, 25
  - see also* dementia praecox
- SCN (suprachiasmatic nucleus), 356
- seasonal affective disorder (SAD), 97
  - comorbidity, 99
  - concept of, 99–100
  - diagnostic criteria, 100
  - differential diagnosis, 99–100
  - genetic factors, 361
  - light therapy, 284–85
- seasonal disorders, 9, 46
- seizures
  - drug effects on, 188
  - electroencephalography, 321
  - pentylenetetrazol-induced, 161
- selective serotonin reuptake inhibitors (SSRIs), 50
  - development, 312
  - effectiveness, 202, 312
  - children and adolescents, 244, 248–49
  - elderly, 253–54
  - issues, 312–13
  - effects on sleep, 357
  - effects on suicide rates, 140, 141
  - studies, 141–42
  - and electroconvulsive therapy compared, 156
  - limitations, 197
  - manic-depressive illness treatment, 226
  - neonatal issues, 241–42
  - overdose, lethality, 142–43

541 Index

- Parkinson's disease with melancholia
  - treatment, 259
- and placebo response, 201
- vs non-tricyclic antidepressants, 204–206
- vs tricyclic antidepressants, 196, 198–00, 201–204, 206–207
- selegiline, Parkinson's disease with melancholia
  - treatment, 259
- Selye, Hans, 62–63
- sensitization model, of manic-depressive illness, 328
- sensory evoked potentials (SEPs), 323–26
- mood disorder studies, 324
- serotonin
  - dysfunction, and melancholia, 312–13
  - estrogen effects on, 307, 313
  - function
    - animal studies, 313–12
    - in depressive mood disorders, 312–13
    - levels, and suicide risk, 138
- serotonin reuptake transporter (SERT), 359–60
- sertraline
  - and breast-feeding, 244
  - drug-switching, 214
  - effectiveness, 204
  - adolescents, 248
  - children, 248
  - elderly, 251, 253
  - effects on suicide rates, 141
  - heart disease with melancholia treatment, 263–64
  - mania induction, 23
  - Parkinson's disease with melancholia treatment, 258–59
  - post-stroke depression treatment, 258
  - studies, 202
- Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART), 263–64
- SERT (serotonin reuptake transporter), 359–60
- serum prolactin, in electroconvulsive therapy
  - evaluation, 186
- severe melancholia
  - abnormal brain structure, 320
  - depression with catatonia or stupor as, 30
  - pharmacotherapy, 222–29
  - treatment recommendations, 230
- sex differences
  - sleep electroencephalography, 76
  - suicide rates, 125
- SFBN (Stanley Foundation Bipolar Network), 22–23
- signal transduction, abnormalities, 360
- single photon emission computed tomography (SPECT), 117
- sleep
  - and fetal development, 356–57
  - and melancholia prevention, 356–57
- sleep apnea
  - and melancholia, 112, 269
  - symptoms, 112
- sleep deprivation, and mood, 326–27
- sleep disturbances
  - depressed patients, 73, 325–27
  - drug-induced, 205–206
  - and melancholia, 269
  - and relapse, 73
  - and sleep electroencephalography, 326
  - and suicide risk, 138
  - see also* hemispheric sleep phase coherence
- sleep electroencephalography
  - advantages, 78, 320
  - depression studies, 73–74, 76
  - sex differences, 76
  - with dexamethasone suppression test, 75
  - discriminant index scores, 73
  - hemisphere coherence, 76
  - as melancholia indices, 348
  - melancholia studies, 73–76, 325–26
  - and neuroendocrine abnormalities, 63
  - and sleep disturbances, 326
- sleep laboratory tests, 24
- sleep variables, and neuroendocrine variables, 74–75
- smoking cessation, strategies, 256
- solvent abuse, and melancholia, differential diagnosis, 110
- SPECT (single photon emission computed tomography), 117
- sporadic pure depressive disease, 19
- SSRIs *see* selective serotonin reuptake inhibitors (SSRIs)
- Stanley Foundation Bipolar Network (SFBN), 22–23
- STEP-BD algorithm, 23
- stimulants
  - drug augmentation, 216
  - post-stroke depression treatment, 258
- stress
  - childhood, 306
  - cycles of, 332–33
  - and depressive mood disorders, 129–30
  - misdiagnosis, 129
  - effects on metabolism, 62–63
- stress responses
  - abnormal, in melancholia, 307–11
  - animal studies, 306, 308
  - child abuse, 306
  - genetically influenced, 303
  - intrauterine, 304
  - mechanisms, 307–11, 363
  - murine studies, 303
  - neurotoxic effects, reduction, 362–63
  - physiologic effects, 308
  - and sympathetic arousal, 309
  - and temperament, 302
- stroke
  - antidepressant prophylaxis, 257–58
  - cerebrovascular, 114
  - and depressive mood disorders, 317
  - with melancholia, pharmacotherapy, 257–58
  - see also* post-stroke depression

542 Index

- structured interviews
  - limitations, 85
  - procedures, 85
- stupor
  - case studies, 32
  - differential diagnosis, 30
- Styron, William, and melancholia, 18
- sub-Saharan Africa, suicide rates, 125
- substance abuse
  - and depressive mood disorders, 256
  - drugs, 255, 256
  - solvents, 110
  - and suicide risk, 137
  - see also* alcohol abuse
- substance-induced mood disorder, 46
- substance P, roles, 317
- subsyndromal depression, 46
- succinylcholine, 183
- suicidal melancholic patients
  - case studies, 125
  - contact schedules, 145
  - hospitalization, 143–45
    - guidelines, 143
    - indications, Table 7.3, 143
  - inpatient care, 143–45
  - management, 143–45
    - case studies, 145
  - outpatient care, 144–45
  - removal of lethal means, 145
  - supervision, 145
  - symptom relief, 145
- suicidal thoughts
  - and alcohol use, 137
  - case studies, 131
  - clinical examination, 90
  - communication, 131
  - concealed, 131
  - and decreased capacity, 127
- suicide
  - and firearms, 125–26, 133, 137
    - case studies, 133
  - in manic-depressive illness, 136
  - in melancholia, 125–45
- suicide prevention
  - and antidepressants, 132
  - errors in, 126–31
  - measures for, 138
- suicide rates
  - age differences, 125, 126
  - antidepressant treatment effects, 140–42
  - depressed patients, 125
  - ethnic and racial differences, 126
  - global estimates, 125
  - lithium treatment effects, 139–40
  - psychotic depression, 223
  - sex differences, 125
  - and treatment type, 139–43
- suicide risk
  - and adjustment disorder with depressed mood, 102
  - and alcohol abuse, 137
  - antidepressants vs electroconvulsive therapy, 159
  - case studies, 132, 133, 137
  - and depressive mood disorders, 125
  - and dexamethasone suppression test, 68, 138–39
  - and electroconvulsive therapy, 159–61
    - case studies, 160–61
  - and failure to administer electroconvulsive therapy, 134
  - and failure to hospitalize, 133–34
  - and failure to recognize depressive mood disorders, 126–29
  - familial, 135–36
  - and hospitalization, 135, 143–44
    - guidelines, 143
  - inadequate outpatient follow-up, 132–33
  - inadequate pharmacotherapy, 132, 141
    - studies, 132
  - and involuntary commitment, 133–34
  - laboratory measures, 138–39
  - males, over 50 years of age, 136–37
  - and medical illness, 137–38
  - and neurological illness, 137–38
  - and psychotic depression, 89
  - and serotonin levels, 138
  - and sleep disturbances, 138
  - and substance abuse, 137
  - twin studies, 135–36
  - under-diagnosis, 126–29
    - studies, 127
- suicide risk assessment, 134–36
  - factors, 1298
  - inadequate, 130–31
    - case studies, 131
  - long-term, 131
  - training, 134–35
- super-ego, 6
- superimposed depression, diagnostic criteria, 106
- suprachiasmatic nucleus (SCN), 356
- Sweden, depression, prevalence, 49
- Swedish Birth Registry, 241
- sympathetic arousal, and stress responses, 309
- syndromes
  - Asperger, 104
  - avolitional, 113
  - bradykinetic, 113
  - Capgras, 30
  - de Clérambault, 30
  - definitions, 51–52
    - empirical, 52
    - expert consensus, 51–52
  - Ganser, 30
  - melancholia as, 58
  - Othello, 30
  - post-concussion, 115
  - see also* apathetic syndromes; Cotard syndrome; Cushing's syndrome; neuroleptic malignant syndrome (NMS)
- syphilis
  - cerebral, 4
  - and depression, 111
  - serological identification, 62

543 Index

- T<sub>3</sub> *see* triiodothyronine (T<sub>3</sub>)
- T<sub>4</sub> (thyroxine), 72
- tachycardia, risk factors, 262
- TADS (Treatment for Adolescents with Depression Study), 249
- targeted neurotransmitter system agents, in melancholia treatment, 290
- Taylor, Michael Alan, 19, 27
- TBI *see* traumatic brain injury (TBI)
- TCAs *see* tricyclic antidepressants (TCAs)
- temperament
  - children, 302
  - and environmental factors, 302
  - genetic factors, 332
  - and heritability, 302
  - and melancholia risk, 302
  - personality traits, 91
  - and stress responses, 302
  - unstable, 330
  - use of term, 302
- Tennessee (USA), electroconvulsive therapy, adolescents, 165
- teratogenicity, antidepressants, 240–41
- testosterone, in melancholia treatment, 292
- Texas (USA), electroconvulsive therapy, adolescents, 165
- thalamus, and stress responses, 308, 309–11
- theophylline, effects on seizure, 188
- thioridazine, drug–drug interactions, 265
- threshold model, 56, 57
- thrombosis, risk factors, 262
- thyroid, functions, 72
- thyroid disease
  - differential diagnosis, 111
  - etiology, 111
  - with melancholia, pharmacotherapy, 265
- thyroid dysfunction, and treatment-resistant depression, 272
- thyroid function tests, 63
- thyroid-stimulating hormone (TSH), 72
  - levels
    - and depression, 72
    - and mania, 330
    - and melancholia, 307
- thyrotropin-releasing hormone (TRH), 72
  - levels, and depression, 72
  - and melancholia, 307
- thyroxine (T<sub>4</sub>), release, 72
- TMS *see* transcranial magnetic stimulation (TMS)
- topiramate, 290
- transcranial magnetic stimulation (TMS)
  - effectiveness, 287–88
  - and electroconvulsive therapy compared, 286–87
  - in melancholia treatment, 286–88
- transcription cascades, 360
- transcription factors, 360
- tranylcypromine, 50
  - effectiveness, children and adolescents, 249
- traumatic brain injury (TBI)
  - differential diagnosis, 115
  - with melancholia, pharmacotherapy, 261
- trazodone, side-effects, 205–206
- TRD *see* treatment-resistant depression (TRD)
- Treatment for Adolescents with Depression Study (TADS), 249
- treatment algorithms, 47–48, 348, 364–65
  - STEP-BD, 23
- treatment guidelines, recommendations, 351
- treatment resistance, 212–13
- treatment-resistant depression (TRD)
  - case studies, 270
  - comorbidity, 270–72
  - and electroconvulsive therapy, failure to provide, 272–73
  - inadequate treatment, 270
  - incorrect diagnosis, 268–70
  - pharmacotherapy, 268–73
  - prevention, 273
  - and thyroid dysfunction, 272
- treatment trials, recommendations, 349–51
- treatment type, and suicide rates, 139–43
- TRH *see* thyrotropin-releasing hormone (TRH)
- tricyclic antidepressants (TCAs)
  - advantages, 197, 202
  - approved, 50
  - and breast-feeding, 244
  - dosing issues, 247–48
  - drug augmentation, 217
  - effectiveness, 202
    - children, 244, 246–48
    - elderly, 252
  - effects on suicide rates, 140
  - and electroconvulsive therapy
    - compared, 156, 157
  - epilepsy with melancholia treatment, 260
  - heart disease with melancholia treatment, 262–63
  - mania induction, 22
  - manic-depressive illness treatment, 226
  - melancholia treatment, 206–207
  - neonatal issues, 241, 242
  - overdose, lethality, 142–43
  - Parkinson's disease with melancholia treatment, 258–59
  - psychosis studies, 25
  - secondary vs tertiary amines, 199, 211
  - side-effects, 205, 252, 260
  - treatment resistance, 103
  - vs selective serotonin reuptake inhibitors, 196, 198–00, 201–204, 206–207
- triiodothyronine (T<sub>3</sub>)
  - drug augmentation, 216
  - and melancholia, 307
  - release, 72
- tryptophan hydroxylase, 360
- TSH *see* thyroid-stimulating hormone (TSH)
- twin studies
  - bipolar–unipolar overlap, 23
  - depression, 49
  - depressive mood disorders, 301, 303
  - manic-depressive illness, 330



544 Index

- twin studies (*cont.*)
  - premenstrual dysphoric disorder, 102
  - suicide risk, 135–36
- two depression factors, Kendell’s, 53, 54–55
- UFC (urinary free cortisol), 67
- unipolar depression, 46
  - early studies, 19
  - electroconvulsive therapy, 172–74
  - recurrent, 21
  - subtypes, 19
- unipolar disorder, psychopathologic studies, 20
- unitary model, 5
- United Kingdom (UK)
  - antidepressants
    - prescriptions issued, 141–42
    - regulations, 141
    - and suicide rates, 141–42
- United States of America (USA)
  - antidepressants
    - studies, 142
    - and suicide risk, 141
  - electroconvulsive therapy, adolescents, 165
  - St. John’s wort studies, 293
  - suicide rates, 125, 126
    - ethnic and racial differences, 126
  - suicide risk assessment, training, 134–35
- University of Melbourne (Australia), 64–65
- University of Michigan (USA), 64–65
  - electroconvulsive therapy studies, 166
- urinary free cortisol (UFC), 67
- urine copper assays, 116
- vagal nerve stimulation (VNS)
  - in melancholia treatment, 289
  - recommendations, 289
- valproic acid
  - drug–drug interactions, 265
  - manic-depressive illness treatment, 228, 229
  - severe melancholia treatment, 230
- vascular brain disease, elderly, 251
- vascular depression
  - age of onset, 105
  - use of term, 105
- vascular disease, and depression, 106
- vasoactive intestinal polypeptide (VIP),
  - roles, 317
  - vasopressin, roles, 316–17
- vegetative functions, and melancholia, 16
- vegetative signs
  - clinical examination, 88–89
  - and melancholia, 348
- venlafaxine
  - diabetes with melancholia
    - treatment, 264–65
  - effectiveness, 202, 203, 205, 224
  - effects on suicide rates, 141
  - heart disease with melancholia
    - treatment, 263
  - Huntington’s disease with melancholia
    - treatment, 260
  - mania induction, 23
  - melancholia treatment, 211
  - Parkinson’s disease with melancholia
    - treatment, 259
  - severe melancholia treatment, 230
  - side-effects, 263
  - toxicity, 142
- ventrolateral cortex, increased metabolism, 319–20
- VEPs *see* visual evoked potentials (VEPs)
- Veraguth’s folds, 87
- verbal memory, impairment, 327
- Verblödungsprozesse*, 4
- VIP (vasoactive intestinal polypeptide), 317
- visual evoked potentials (VEPs), 323–24
  - mood disorder studies, 324
- visual memory, impairment, 327
- vital depression, 8
- VNS *see* vagal nerve stimulation (VNS)
- warfarin, drug–drug interactions, 265
- Washington state (USA), 241
- Weissenburger, J. E. 57
- white matter, 116
  - changes, 105, 106
- Wilson’s disease, differential diagnosis, 116
- witchcraft, and mental disorders, 3
- Witzelsucht* (shallow humor), 113–14
- World Health Organization (WHO), depression studies, 351
- ziprasidone, 224
- Ziskind, E., 154, 155
- Zung Self-rating Depression Scale (ZSDS), 94